

Cationic Perylene Antivirals with Aqueous Solubility for Studies in vivo

Supplementary materials

Anna A. Shtro^{1,†,*}, **Anzhelika V. Garshinina**^{1,†}, **Vera A. Alferova**^{2,3,†}, **Polina N. Kamzeeva**²,
Viktor P. Volok^{2,4}, **Ekaterina S. Kolpakova**⁴, **Timofei D. Nikitin**², **Alexey A. Chistov**²,
Evgeny S. Belyaev⁵, **Vladimir A. Korshun**², **Liubov I. Kozlovskaya**^{4,6,*} and **Andrey V. Aralov**^{2,*}

¹ Smorodintsev Research Institute of Influenza, Saint Petersburg, 197376, Russia

² Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia

³ Gause Institute of New Antibiotics, Moscow, 119021, Russia

⁴ Chumakov Scientific Center for Research and Development of Immune-and-Biological Products (Institute of poliomyelitis), Russian Academy of Sciences, Moscow, 108819, Russia

⁵ Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Science, Moscow, 119071, Russia

⁶ Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, Moscow, 119991, Russia

* Correspondence: aashtro@gmail.com (A.A.S.); lubov_i_k@mail.ru (L.I.K.); baruh238@mail.ru (AVA)

† These authors contributed equally to this work.

CONTENTS

Figure S1. ^1H and ^{13}C NMR spectra of the compound 2a	3
Figure S2. ^1H and ^{13}C NMR spectra of the compound 2b	4
Figure S3. ^1H and ^{13}C NMR spectra of the compound 3a	5
Figure S4. ^1H and ^{13}C NMR spectra of the compound 3b	6
Figure S5. ^1H and ^{13}C NMR spectra of the compound 5	7
Figure S6. ^1H and ^{13}C NMR spectra of the compound 6	8
Figure S7. ^1H and ^{13}C NMR spectra of the compound 7	9
Figure S8. ^1H and ^{13}C NMR spectra of the compound 8	10
Figure S9. ^1H and ^{13}C NMR spectra of the compound 10	11
Table S1. Predicted ADMET profiles of the synthesized compounds.	12
Figure S10. Serum stability evaluation.	14
Figure S11. HPLC trace for compound 3a	15
Figure S12. HPLC trace for compound 3b	16
Figure S13. HPLC trace for compound 8	17
Figure S14. HPLC trace for compound 10	18

Figure S1. ^1H and ^{13}C NMR spectra of the compound **2a**.




Figure S2. ^1H and ^{13}C NMR spectra of the compound **2b**.




Figure S3. ^1H and ^{13}C NMR spectra of the compound **3a**.




Figure S4. ^1H and ^{13}C NMR spectra of the compound **3b**.




Figure S5. ^1H and ^{13}C NMR spectra of the compound 5.




Figure S6. ^1H and ^{13}C NMR spectra of the compound 6.




Figure S7. ^1H and ^{13}C NMR spectra of the compound 7.




Figure S8. ^1H and ^{13}C NMR spectra of the compound **8**.




Figure S9. ^1H and ^{13}C NMR spectra of the compound **10**.













Table S1. Predicted ADMET profiles of the synthesized compounds

compound	Structure	cHIA ^a	clogBB ^b
2a		85.4	0.17
2b		99.97	0.25
3a		10.06	0.04
3b		10.06	0.13
5		83.25	-0.67

6		73.26	0.03
7		42.53	0.53
8		42.53	-0.6
10		97.22	0.01

^a HIA – human intestinal absorption [%],

^b LogBB – blood-brain barrier permeability.

[Back to Contents](#)

Figure S10. Serum stability evaluation




Figure S11. HPLC trace for compound **3a**

Data File C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-09 22-13-29\005-P2-A8-545.D
Sample Name: 545

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    5
Sample Operator : SYSTEM
Acq. Instrument : LCMS                      Location  : P2-A-08
Injection Date  : 9/9/2022 11:38:16 PM      Inj       :    1
                                           Inj Volume: 2.000 µl
Different Inj Volume from Sample Entry! Actual Inj Volume : 5.000 µl
Acq. Method     : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-09 22-13-29
                  \Purity_test450_SEQ.M
Last changed    : 9/9/2022 10:13:26 PM by SYSTEM
Analysis Method : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-09 22-13-29
                  \Purity_test450_SEQ.M (Sequence Method)
Last changed    : 9/13/2022 3:37:42 PM by SYSTEM
                  (modified after loading)
Additional Info  : Peak(s) manually integrated
```




Figure S12. HPLC trace for compound **3b**

Data File C:\Users\P...\ChemStation\1\Data\Seq1 2022-09-13 16-06-50\007-P1-A3-ARVI-20-16.D
Sample Name: ARVI-20-16

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    7
Sample Operator : SYSTEM
Acq. Instrument : LCMS                      Location  : P1-A-03
Injection Date  : 9/13/2022 5:59:42 PM      Inj       :    1
                                           Inj Volume: 2.000 µl
Different Inj Volume from Sample Entry! Actual Inj Volume : 20.000 µl
Acq. Method     : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50
                  \Purity_test450_SEQ.M
Last changed    : 9/9/2022 10:13:26 PM by SYSTEM
Analysis Method : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50
                  \Purity_test450_SEQ.M (Sequence Method)
Last changed    : 9/13/2022 6:37:22 PM by SYSTEM
                  (modified after loading)
Additional Info  : Peak(s) manually integrated
```




Figure S13. HPLC trace for compound 8

Data File C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50\009-P1-A4-AR554.D
Sample Name: AR554

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    9
Sample Operator : SYSTEM
Acq. Instrument : LCMS                      Location  : P1-A-04
Injection Date  : 9/13/2022 6:35:09 PM      Inj       :    1
                                           Inj Volume: 2.000 µl
Different Inj Volume from Sample Entry! Actual Inj Volume : 10.000 µl
Acq. Method     : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50
                  \Purity_test450_SEQ.M
Last changed    : 9/9/2022 10:13:26 PM by SYSTEM
Analysis Method : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50
                  \Purity_test450_SEQ.M (Sequence Method)
Last changed    : 9/13/2022 6:53:31 PM by SYSTEM
                  (modified after loading)
Additional Info  : Peak(s) manually integrated
```




Figure S14. HPLC trace for compound 10

Data File C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50\005-P2-A5-AR542.D
Sample Name: AR542

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    5
Sample Operator : SYSTEM
Acq. Instrument : LCMS                      Location  : P2-A-05
Injection Date  : 9/13/2022 5:22:10 PM      Inj       :    1
                                           Inj Volume: 2.000 µl
Different Inj Volume from Sample Entry! Actual Inj Volume : 5.000 µl
Acq. Method     : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50
                                           \Purity_test530_SEQ.M
Last changed    : 9/9/2022 10:05:11 PM by SYSTEM
Analysis Method : C:\Users\Public\Documents\ChemStation\1\Data\Seq1 2022-09-13 16-06-50
                                           \Purity_test530_SEQ.M (Sequence Method)
Last changed    : 9/13/2022 5:44:50 PM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated
```

